PL2936151T3 - Sposoby leczenia i/lub ograniczania rozwoju cukrzycy - Google Patents
Sposoby leczenia i/lub ograniczania rozwoju cukrzycyInfo
- Publication number
- PL2936151T3 PL2936151T3 PL13811451T PL13811451T PL2936151T3 PL 2936151 T3 PL2936151 T3 PL 2936151T3 PL 13811451 T PL13811451 T PL 13811451T PL 13811451 T PL13811451 T PL 13811451T PL 2936151 T3 PL2936151 T3 PL 2936151T3
- Authority
- PL
- Poland
- Prior art keywords
- diabetes
- treating
- methods
- limiting development
- development
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/507—Pancreatic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261738835P | 2012-12-18 | 2012-12-18 | |
EP13811451.7A EP2936151B1 (en) | 2012-12-18 | 2013-12-17 | Methods for treating and/or limiting development of diabetes |
PCT/EP2013/076917 WO2014095875A1 (en) | 2012-12-18 | 2013-12-17 | Methods for treating and/or limiting development of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2936151T3 true PL2936151T3 (pl) | 2018-11-30 |
Family
ID=49876594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13811451T PL2936151T3 (pl) | 2012-12-18 | 2013-12-17 | Sposoby leczenia i/lub ograniczania rozwoju cukrzycy |
Country Status (10)
Country | Link |
---|---|
US (1) | US9068971B2 (pl) |
EP (1) | EP2936151B1 (pl) |
JP (1) | JP6322209B2 (pl) |
KR (1) | KR102141898B1 (pl) |
CN (1) | CN105051534B (pl) |
DK (1) | DK2936151T3 (pl) |
ES (1) | ES2689922T3 (pl) |
HK (1) | HK1214355A1 (pl) |
PL (1) | PL2936151T3 (pl) |
WO (1) | WO2014095875A1 (pl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3256118A1 (en) | 2015-02-09 | 2017-12-20 | BioCrine AB | Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis |
CA2996064C (en) * | 2015-08-18 | 2024-02-13 | Novation Pharmaceuticals Inc. | Benzopyran derivatives and uses thereof |
EP3383869B1 (en) | 2015-11-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Aryl sulfonamides as blt1 antagonists |
WO2017095724A1 (en) * | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl sulfonamides as blt1 antagonists |
DE202017007491U1 (de) * | 2016-12-02 | 2022-01-07 | Sophion Bioscience A/S | Dichtungsverstärker |
CN113967210A (zh) * | 2020-07-24 | 2022-01-25 | 上海交通大学医学院附属瑞金医院 | 一种干扰整合素β3/Src相互作用的化合物的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486299B1 (en) * | 1998-09-28 | 2002-11-26 | Curagen Corporation | Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity |
JP2002080499A (ja) * | 2000-09-01 | 2002-03-19 | Suntory Ltd | カルシウムチャンネル阻害作用を有する新規ペプチド |
EP1562605A4 (en) | 2002-10-08 | 2006-07-12 | Massachusetts Inst Technology | COMPOUNDS FOR MODULATING CHOLESTER INTRANSPORT |
ATE409046T1 (de) * | 2003-03-12 | 2008-10-15 | Rappaport Family Inst For Res | Zusammensetzungen und verfahren zur diagnose und behandlung einer entzündung |
PL1623228T3 (pl) * | 2003-04-29 | 2013-04-30 | Biocrine Ab | APOCIII i leczenie oraz diagnozowanie cukrzycy |
CA2622911C (en) * | 2005-09-16 | 2016-12-06 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
WO2009128734A1 (en) * | 2008-04-18 | 2009-10-22 | Vialactia Biosciences (Nz) Limited | Marker assisted identification of mammals for desired phenotypic trait |
US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
-
2013
- 2013-12-17 EP EP13811451.7A patent/EP2936151B1/en active Active
- 2013-12-17 ES ES13811451.7T patent/ES2689922T3/es active Active
- 2013-12-17 US US14/108,597 patent/US9068971B2/en active Active
- 2013-12-17 WO PCT/EP2013/076917 patent/WO2014095875A1/en active Application Filing
- 2013-12-17 JP JP2015547072A patent/JP6322209B2/ja active Active
- 2013-12-17 PL PL13811451T patent/PL2936151T3/pl unknown
- 2013-12-17 DK DK13811451.7T patent/DK2936151T3/en active
- 2013-12-17 CN CN201380061912.3A patent/CN105051534B/zh not_active Expired - Fee Related
- 2013-12-17 KR KR1020157016308A patent/KR102141898B1/ko active IP Right Grant
-
2016
- 2016-02-26 HK HK16102230.8A patent/HK1214355A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150096676A (ko) | 2015-08-25 |
EP2936151A1 (en) | 2015-10-28 |
JP6322209B2 (ja) | 2018-05-09 |
CN105051534B (zh) | 2017-08-18 |
US20140170113A1 (en) | 2014-06-19 |
US9068971B2 (en) | 2015-06-30 |
CN105051534A (zh) | 2015-11-11 |
JP2016510210A (ja) | 2016-04-07 |
HK1214355A1 (zh) | 2016-07-22 |
WO2014095875A1 (en) | 2014-06-26 |
ES2689922T3 (es) | 2018-11-16 |
EP2936151B1 (en) | 2018-07-18 |
KR102141898B1 (ko) | 2020-08-06 |
DK2936151T3 (en) | 2018-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2675459A4 (en) | COMPOUNDS AND METHODS FOR TREATING DIABETES | |
HK1251796A1 (zh) | 治療糖尿病的方法和組合物 | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
EP2887805A4 (en) | COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE | |
HK1204450A1 (en) | Methods of treating celiac disease | |
HK1209633A1 (en) | Compositions and methods for treating diabetes | |
EP2874647A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT | |
HK1200348A1 (en) | Methods and materials for treatment of pompes disease | |
EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
HK1214355A1 (zh) | 用於治療和/或限制糖尿病發展的方法 | |
GB201217296D0 (en) | Method of treatment and/or prevention | |
EP2888370A4 (en) | DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES | |
EP2836804A4 (en) | DEVICE AND METHOD FOR DETERMINING SAFE TANNING TIME | |
IL234606A0 (en) | Innovative methods and compounds for the treatment of diseases | |
EP2804614A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND / OR ADIPOSITAS | |
ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
HK1210077A1 (en) | Methods of treating or preventing respiratory conditions | |
HK1206791A1 (en) | Means and methods for response prediction of hepatitis b treatment | |
HK1212999A1 (zh) | 用於治療和/或限制糖尿病的發展的方法 | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
PL2864417T3 (pl) | Polimer i sposób zastosowania | |
HK1202819A1 (en) | Treatment of type i and type ii diabetes i ii | |
HK1223034A1 (zh) | 用於治療 型糖尿病的方法和養生方案 | |
GB201221032D0 (en) | Method of treatment | |
GB201207894D0 (en) | Method of treatment |